Success Metrics

Completion Rate
0%(0/1)
Active Trials
3(50%)
Terminated
1(17%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
2
33%

Phase Distribution

4

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
2(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 2 finished

Non-Completion Rate

100.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Terminated(2)
Other(1)

Detailed Status

Recruiting2
Terminated1
Withdrawn1
Active, not recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 22 (33.3%)

Trials by Status

terminated117%
withdrawn117%
active_not_recruiting117%
recruiting233%
suspended117%

Recent Activity

3 active trials
Showing 5 of 6
recruitingphase_1

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

NCT04615013
suspendedphase_1

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

NCT04484909
active_not_recruitingphase_1

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

NCT04505267
recruitingphase_1

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

NCT05039632
terminatedphase_2

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

NCT04862455
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT04615013Phase 1

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Recruiting
NCT04484909Phase 1

NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer

Suspended
NCT04505267Phase 1

NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer

Active Not Recruiting
NCT05039632Phase 1

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

Recruiting
NCT04862455Phase 2

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Terminated
NCT04834349Phase 2

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Withdrawn

All 6 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
6